Congestive Heart Failure (CHF)

Questions for Deliberation: October 29, 2015 Public Meeting

**Entresto**

1. For patients with Class II-IV levels of CHF and reduced ejection fraction, is the evidence adequate to demonstrate that the net health benefit of *Entresto* is greater than that of *usual care with ACE inhibitors*?
   - Yes
   - No

2. Given the available evidence for patients with Class II-IV CHF and reduced ejection fraction, what is the care value of *Entresto* vs. *usual care with ACE inhibitors*?
   - a. Low
   - b. Intermediate
   - c. High

3. Given the available evidence for patients with Class II-IV CHF and reduced ejection fraction, what is the provisional health system value of *Entresto*?  
   - a. Low
   - b. Intermediate
   - c. High

**CardioMEMS**

4. For patients with Class III CHF and a hospitalization in the prior 12 months, is the evidence adequate to demonstrate that the net health benefit of *CardioMEMS* is greater than *usual care*?
   - Yes
   - No

5. Given the available evidence for patients with Class III CHF and a hospitalization in the prior 12 months, what is the care value of *CardioMEMS* vs. *usual care*?
   - a. Low
   - b. Intermediate
   - c. High

6. Given the available evidence for patients with Class III CHF and a hospitalization in the prior 12 months, what is the provisional health system value of including *CardioMEMS* in CHF care management?
   - a. Low
   - b. Intermediate
   - c. High